Browse by category

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether, obesity experts from King's College London and the Obesity Management Collaborative (OMC-UK) have warned. They stated that strict eligibility criteria means that only a small number of people will have access to the weight loss drug tirzepatide (Mounjaro) on the NHS, with those able to afford it paying privately for treatment. The researchers argue, in an edi

High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to...

Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke...

Sleep medicine professionals favour continuous positive airway pressure therapy as treatment for comorbid obesity and obstructive sleep...

Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five...

A recent analysis of the SURPASS-3 trial indicates that decreases in muscle volume with tirzepatide largely followed the overall...

Tirzepatide decreased participants’ calorie intake at lunch/dinner by reducing appetite while increasing fat oxidation, thus helping...

Skye Bioscience's novel CB1 antibody, nimacimab in combination with the dual GLP-1/GIP agonist, tripeptide, resulted in greater than 30%...

Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection...